Group 1 - The core viewpoint of the article highlights the significant growth and strategic developments of Tianfeng Securities, particularly in relation to its support for He Yuan Bio's IPO and its new status as a controlled entity under Hubei Hongtai Group [1][3]. - He Yuan Bio, a star enterprise in innovative "rice blood-making" technology, has seen its market value increase from 60 million to over 30 billion, a growth of more than 500 times over 15 years, with Tianfeng Securities playing a crucial role in its investment journey [1]. - In 2023, Hubei Hongtai Group became the controlling shareholder of Tianfeng Securities, filling a gap in provincial state-owned capital controlling brokerages and enhancing local financial stability [1][3]. Group 2 - For the first nine months of this year, Tianfeng Securities achieved a total operating income of 2.112 billion, a year-on-year increase of 57.53%, and a net profit attributable to shareholders of 153 million, marking a turnaround from losses [3]. - As of the end of October 2023, Tianfeng Securities' total market value reached 59.23 billion, an increase of 27.57 billion since Hubei Hongtai Group took control in March 2023, elevating its market ranking among A-share listed companies from 16th to 5th [3]. - Tianfeng Securities has actively supported local economic development by facilitating financing of nearly 930 billion over the past three years, including approximately 120 billion for Hubei enterprises [3]. Group 3 - A signing ceremony was held at the conference, where Tianfeng Securities signed cooperation agreements with 22 banking institutions, including major banks like the Export-Import Bank and Agricultural Bank, to enhance collaboration in supporting local economic development [4].

Group 1 - The core viewpoint of the article highlights the significant growth and strategic developments of Tianfeng Securities, particularly in relation to its support for He Yuan Bio's IPO and its transformation under Hubei Hongtai Group's control [2][3]. - He Yuan Bio, a star enterprise in innovative "rice blood-making" technology, successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with its market value increasing from 60 million to over 30 billion, a growth of over 500 times [2]. - Tianfeng Securities has played a crucial role in He Yuan Bio's journey, from early angel investment to participating in its Pre-IPO round, and facilitating strategic allocations during the IPO process [2]. Group 2 - In the first nine months of this year, Tianfeng Securities achieved a total operating income of 2.112 billion yuan, a year-on-year increase of 57.53%, and net profit attributable to shareholders of the parent company reached 153 million yuan, marking a turnaround from losses [3]. - As of the end of October 2023, Tianfeng Securities' total market value reached 59.23 billion yuan, an increase of 27.57 billion yuan since Hubei Hongtai Group became the controlling shareholder in March 2023, elevating its market ranking among A-share listed companies in Hubei from 16th to 5th [3]. - Tianfeng Securities has significantly contributed to the financing of the real economy, with nearly 930 billion yuan raised over the past three years, including approximately 120 billion yuan for Hubei enterprises [4].